In-vitro activated mixed cell cancer vaccine containing dendritic cells and b cells, and use thereof

By activating dendritic cells and B cells in vitro and co-incubating them with antigen delivery particles to form a mixed cell vaccine, the problem of poor vaccine effectiveness caused by insufficient dendritic cells in the prior art was solved, and the efficacy and immunity of cancer vaccines were significantly improved. Treatment effect.

WO2024250376A1PCT designated stage expired Publication Date: 2024-12-12SUZHOU ERSHENG BIOPHARMACEUTICAL CO LTD
View PDF 3 Cites 1 Cited by

Patent Information

Application Number
PCT/CN2023/106906
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-07
Filing Date
2023-07-12
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

The existing cancer vaccines are not effective, especially in patients with reduced immune cells. Insufficient dendritic cell content leads to poor vaccine effectiveness, and relying on dendritic cell activation alone cannot effectively activate the T cell immune response.

Method used

By activating dendritic cells and B cells in vitro, co-incubating with dendritic cells and B cells using antigen delivery particles to form a mixed cell cancer vaccine, improving the efficiency of immune response.

Benefits of technology

It significantly improves the efficacy of cancer vaccines, especially in patients with reduced immune cells, enhances the effect of immunotherapy, supplements immune-capable living cells, and helps cure diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023106906_12122024_PF_FP_ABST
    Figure CN2023106906_12122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are an in vitro activated mixed cell cancer vaccine containing dendritic cells and B cells, and a use thereof. The mixed cell vaccine is obtained by simultaneously activating dendritic cells and B cells in vitro by means of antigen delivery particles; the antigen delivery particles are nanoparticles and / or micronparticles loaded with an antigen component; the antigen component is derived from one or more of the following: (1) a water-soluble component and / or a non-water-soluble component in cancer cells and / or cells in a tumor tissue; (2) a protein and a polypeptide component in the water-soluble component and / or non-water-soluble component; (3) an RNA component in the water-soluble component and / or non-water-soluble component; (4) a protein and / or polypeptide synthesized in vitro and containing an antigen polypeptide epitope; and (5) a nucleic acid synthesized in vitro and capable of expressing an antigen polypeptide epitope. In the present invention, the current technical prejudice against the effect of initial activation of T cells by B cells is overcome, and it is found that the mixed cell vaccine system of dendritic cells and B cells is significantly more effective than existing dendritic cell vaccines.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Cancer vaccine based on antigen presentation cell membrane component as well as preparation method and application of cancer vaccine

    CN114931632A

  • Detection method and kit for cancer cell specific T cells

    CN115561145A

  • In-vitro activated mixed cell cancer vaccine containing dendritic cells and B cells and application thereof

    CN116850275A

Cited By

  • Method for preparing dendritic cells of cluster of differentiation 103+FCGR3 + with improved immunogenicity by treating interleukin-33, and pharmaceutical composition for immune anti-cancer treatment comprising dendritic cells

    CN116490196A